This is a working overview of GLP-1 receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
In the U.S., tetrodotoxin appears on the select agents list of the Department of Health and Human Services, and scientists must register with HHS to use tetrodotoxin in their research. However, investigators possessing less than 500 mg are exempt from regulation.
Proteins with GO terms related to polysaccharide binding and processing were enriched for serine and threonine in their LCRs. Proteins with GO terms related to RNA binding and processing were enriched for arginine in their LCRs. Proteins with GO terms related to DNA binding and processing were especially enriched for lysine, but also for glycine, tyrosine, phenylalanine and glutamine in their LCRs. Proteins with GO terms related to metal binding and more specifically to cobalt or nickel-binding were enriched mostly for histidine but also for aspartate in their LCRs. Proteins with GO terms related to protein folding were enriched for glycine, methionine and phenylalanine in their LCRs. Based on the above observations and analyses, a Neural Network webserver named LCR-hound has been developed to predict LCRs and their function.
For coupling to mass spectrometry, the ions from the plasma are extracted through a series of cones into a mass spectrometer, usually a quadrupole. The ions are separated on the basis of their mass-to-charge ratio and a detector receives an ion signal proportional to the concentration. The concentration of a sample can be determined through calibration with certified reference material such as single or multi-element reference standards. ICP-MS also lends itself to quantitative determinations through isotope dilution, a single point method based on an isotopically enriched standard. In order to increase reproducibility and compensate for errors by sensitivity variation, an internal standard can be added. Other mass analyzers coupled to ICP systems include double focusing magnetic-electrostatic sector systems with both single and multiple collector, as well as time of flight systems (both axial and orthogonal accelerators have been used).
Tropic hormones are hormones that have other endocrine glands as their target. Most tropic hormones are produced and secreted by the anterior pituitary. The hypothalamus secretes tropic hormones that target the anterior pituitary, and the thyroid gland secretes thyroxine, which targets the hypothalamus and therefore can be considered a tropic hormone. The term tropic is from Ancient Greek τροπικός (tropikós), in the sense "of or pertaining to a turn or change", meaning "causing a change, affecting"; this is the same origin as trope. This should not be confused with trophic, as in similar-sounding trophic hormone – the words and concepts are both unrelated. Tropic hormones are contrasted with non-tropic hormones, which directly stimulate target cells.
Sources: en.wikipedia.org
== Structure == IDH1 is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3, and encoded by one of five isocitrate dehydrogenase genes, which are IDH1, IDH2, IDH3A, IDH3B, and IDH3G. IDH1 forms an asymmetric homodimer in the cytoplasm and carries out its function through two hydrophilic active sites formed by both protein subunits. Each subunit or monomer is composed of three domains: a large domain (residues 1–103 and 286–414), a small domain (residues 104–136 and 186–285), and a clasp domain (residues 137 to 185). The large domain contains a Rossmann fold, while the small domain forms an α/β sandwich structure, and the clasp domain folds as two stacked double-stranded anti-parallel β-sheets. A β-sheet joins the large and small domains and is flanked by two clefts on opposite sides. The deep cleft, also known as the active site, is formed by the large and small domains of one subunit and a small domain of the other subunit. This active site includes the NADP-binding site and the isocitrate-metal ion-binding site. The shallow cleft, also referred to as the back cleft, is formed by both domains of one subunit and participates in the conformational changes of homodimeric IDH1. Finally, the clasp domains of both subunits intertwine to form a double layer of four-stranded anti-parallel β-sheets linking together the two subunits and the two active sites. Furthermore, conformational changes to the subunits and a conserved structure at the active site affect the activity of the enzyme.
The BOP was aware that the use of pentobarbital as their "new drug choice" would be challenged in the courts because some lawyers had said that "pentobarbital would flood prisoners' lungs with froth and foam, inflicting pain and terror akin to a death by drowning." BOP claimed that these concerns were unjustified and that their two expert witnesses asserted that the use of pentobarbital was "humane". On 25 July 2019, US Attorney General William Barr directed the federal government to resume capital punishment after 16 years, despite shortages of the compound caused by European Union restrictions and a lack of U.S. manufacturers. The federal protocol provides for intravenous administration of two syringes each containing 2.5 grams of pentobarbital sodium followed by a saline flush.
Statistical Coupling Analysis (SCA) is a method used in bioinformatics to study how pairs of amino acids in a protein sequence evolve together. It analyzes a multiple sequence alignment (MSA), which is a display of the sequences of many related proteins arranged to highlight similarities and differences. SCA measures how much the amino acid makeup at one position in the protein changes when the amino acid makeup at another position is altered. This relationship is quantified as statistical coupling energy. A higher coupling energy indicates that the amino acids at both positions are more likely to have co-evolved and are therefore functionally or structurally linked. In simpler terms, it helps scientists understand which parts of a protein are working together and how they have changed over evolutionary time.
It separately killed Davoud Alizadeh, the commander of the Quds Force's Lebanon Corps, in Tehran. In the night, Hezbollah fired rockets at Tel Aviv and Haifa. By 4 March, more than 300,000 southern Lebanese residents had been displaced due to the conflict. Israeli strikes hit residential areas in Beirut and eastern Lebanon, killing at least 11 people. Two Israeli soldiers were wounded in Lebanon after Hezbollah claimed to have struck a Merkava tank in Houla. On 6 March, a Hezbollah rocket strike in northern Israel injured eight soldiers, five seriously. Later that night, Israeli commandos raided Al-Nabi Shayth in an attempt to recover the remains of missing pilot Ron Arad, leading to a gunbattle that left three Lebanese soldiers dead. Simultaneous airstrikes in the area killed 41 people and injured 40 more. The Israelis withdrew without finding Arad's body. On 8 March, two Israeli soldiers were killed in a separate rocket attack in southern Lebanon. The following day, Hezbollah missiles struck a satellite communications center near Beit Shemesh and a daycare in Ramla in central Israel. On 1 April, an Israeli naval strike in Beirut killed Haj Youssef Ismail Hashem, the commander of Hezbollah's Southern Front. On 8 April, Israeli strikes killed 254 people and wounded more than 1,000 others in central Beirut. Israel Katz said that the strikes targeted hundreds of Hezbollah militants and command centers across Lebanon, in the group's largest blow since the pager attacks. On 16 April, President Trump announced that Israel and Lebanon agreed to a 10-day truce.
A few incidents have occurred when radioactive material was disposed of improperly, shielding during transport was defective, or when it was simply abandoned or even stolen from a waste store. In the Soviet Union, waste stored in Lake Karachay was blown over the area during a dust storm after the lake had partly dried out. In Italy, several radioactive waste deposits let material flow into river water, thus contaminating water for domestic use. In France in the summer of 2008, numerous incidents happened: in one, at the Areva plant in Tricastin, it was reported that, during a draining operation, liquid containing untreated uranium overflowed out of a faulty tank and about 75 kg of the radioactive material seeped into the ground and, from there, into two rivers nearby; in another case, over 100 staff were contaminated with low doses of radiation. There are ongoing concerns around the deterioration of the nuclear waste site on the Enewetak Atoll of the Marshall Islands and a potential radioactive spill. Scavenging of abandoned radioactive material has been the cause of several other cases of radiation exposure, mostly in developing nations, which may have less regulation of dangerous substances (and sometimes less general education about radioactivity and its hazards) and a market for scavenged goods and scrap metal. The scavengers and those who buy the material are almost always unaware that the material is radioactive and it is selected for its aesthetics or scrap value.
Sources: en.wikipedia.org
The findings were published after President Trump and Kennedy both claimed that paracetamol use during pregnancy was contributing to rising autism rates, urging women to avoid the common painkiller. Health experts and the World Health Organization rejected those claims, emphasizing that paracetamol remains the safest recommended medication for fever and pain relief during pregnancy, as untreated fever can pose serious risks to fetal development. Acetaminophen and paracetamol are the identical chemical drug compound. The name acetaminophen (brand name Tylenol) is commonly used in the United States while the name paracetamol (brand name Panadol) is commonly used in Europe and world wide.
Boys argues that Trump uses the theory, deliberately projecting unpredictability and issuing extreme threats to force concessions, citing Venezuela as an example of where defiance was punished, and warning that no country is immune, adding, "I'd be trying to stay well away from everything that's going on with Greenland and the NATO alliance." An article from South China Morning Post suggested that Trump's interest in controlling Greenland, the Panama Canal, Venezuela, and both Iran and the Strait of Hormuz amid the 2026 Iran war and 2026 Strait of Hormuz crisis connects to a wider pattern of superpower nations attempting to seize control of passages and resources.
== Track listing == "Sickman", "Junkhead", "Dirt" and "God Smack" are credited to Cantrell/Staley with no specification for lyrics or music. "Rain When I Die" is credited to Cantrell/Staley/Kinney/Starr, and it was later stated that Cantrell and Staley wrote the lyrics.
== Further reading == Boie F (1827). Bemerkungen über Merrem's Versuch eines Systems der Amphibien, 1te Lieferung: Ophidier. Isis von Oken 20: 508-566. (Cophias wagleri, new species, p. 562). (in German). Boulenger GA (1896). Catalogue of the Snakes in the British Museum (Natural History). Volume III., Containing the ... Viperidæ. London: Trustees of the British Museum (Natural History). (Taylor and Francis, printers). xiv + 727 pp. + Plates I-XXV. (Lachesis wagleri, pp. 562–564).
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.